Medicus Pharma (MDCX)
Develops clinical-stage therapies for skin cancer, urology, oncology, and women’s health.
Something off on this page? Send us feedback.
Develops SkinJect, a microneedle patch for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for oncology, urology, and women’s health. Its partnership-oriented model advances licensed or acquired programs through clinical development rather than selling medicines today.
Develops a pair of clinical-stage therapeutic platforms rather than commercializing medicines itself. SkinJect is a dissolvable microneedle patch designed to deliver doxorubicin into basal cell carcinoma lesions, while Teverelix is a long-acting GnRH antagonist under study for prostate cancer, acute urinary retention, and endometriosis.
Operates through Pennsylvania-based SkinJect and UK-based Antev, with clinical and regulatory activity across the United States, Europe, and the UAE. The model is to acquire or in-license assets, produce mid-stage clinical and regulatory data packages, then seek partnerships, regional licenses, or broader commercialization agreements. Neither platform is approved or generates product revenue; development depends on financing, external collaborators, clinical sites, licensors, and regulator decisions.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Jul 28, 2026 | Industrial Alliance Securities | Target | $1 | |
| Jul 28, 2026 | Alliance Global Partners | Initiate | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.7M · Total debt $15.3M · Total assets $19.1M · Shareholders' equity −$1.2M
- Revenue
- $0
- Operating income
- −$8.3M
- Net income
- −$8.4M
No dividends on record.
| Institutions20 holders · as of Mar 31, 2026 | 3.67% | 2.32M shares | |
| Insiders11 holders · as of Sep 8, 2025 | 10.40% | 6.57M shares | |
| Strategic holders1 holder · as of May 21, 2025 | 10.40% | 6.57M shares | |
| Otherremainder | 75.53% | 47.72M shares |
63.18M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (63.18M in the company's Sep 3, 2026 report, 22.04M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Velocity Fund Partners, LPStrategic10 percent owner | 10.40% | 6.57M | Form 4filed May 21, 2025 ↗ |
Kenneth R. MelaniInsider10 percent owner | 5.26% | 3.32M | Form 4filed Dec 31, 2024 ↗ |
Ajay Raju1Insider10 percent owner | 3.17% | 2.00M | Form 4filed Dec 31, 2024 ↗ |
Interchange Capital Partners, LLCInstitution | 2.63% | 1.66M | 13Fas of Mar 31, 2026 |
Raza Bokhari2Insiderdirector, officer: Chief Executive Officer | 1.26% | 793,173 | Form 4filed Feb 10, 2025 ↗ |
| See all 25 → | |||
- Reported at 3.70% on May 5, 2026, under the 5% line, so no further filing is required.
- Reported at 4.80% on Jan 5, 2026, under the 5% line, so no further filing is required.
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- AbbVie
GnRH therapies span Teverelix's prostate-cancer and endometriosis uses.
- Verrica Pharmaceuticals
Closest investigational non-surgical BCC treatment alternative.
- Regeneron
Approved immunotherapy for advanced BCC after Hedgehog inhibition.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Medicus Pharma | $0.2697 | +4.66% | $5.7M | — | — | — | — |
| AbbVie | $261.51 | −0.08% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Verrica Pharmaceuticals | $5.42 | +3.44% | $92.6M | — | — | 3.1 | −53.9% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Median | 47.4 | 15.6 | 5.7 | +10.2% |